An estimated 2.3 million new cancer cases worldwide in 2024—about 12% of the global total—were attributable to infections, according to an analysis by the International Agency for Research on Cancer. The estimate puts infections among the major potentially preventable contributors to cancer, though the available tools differ sharply by pathogen and by country.
The IARC analysis, published online in The Lancet Oncology on September 28, 2026, is an updated worldwide accounting of cancer burden, not the discovery of a single new cause of cancer. It draws on estimated 2024 incidence from IARC’s Global Cancer Observatory and applies established links between particular infections and cancer types to estimate the number of cases attributable to those infections.
What the one-in-eight estimate measures
The result describes a population-level attributable burden. It does not mean that an infection has been individually confirmed as the cause in every one of the 2.3 million cases, nor does it test whether any one vaccination or screening program reduced cancer rates. Such models depend on cancer-incidence data, estimates of infection prevalence, epidemiological assumptions and established infection-cancer attribution methods.
IARC said the update expanded the list of agents and associations considered, adding HIV and Merkel cell polyomavirus and incorporating newer established links, including Epstein-Barr virus and gastric cancer.
As The Conversation noted in its explanation of the analysis, changes in underlying data sources and data quality make direct comparisons with earlier global estimates unreliable. The 2024 calculation is best understood as an updated snapshot using its own methods and inputs, rather than a trend line.
The infections accounting for the largest estimated burden
Five pathogens made up most of the estimated total. Reporting on the study by Newsweek put the approximate 2024 burden at 760,000 cases associated with Helicobacter pylori, 750,000 with human papillomavirus, 360,000 with hepatitis B virus, 260,000 with Epstein-Barr virus and 160,000 with hepatitis C virus.
These are modelled population-level estimates, rather than counts based on the infection status of each patient. They indicate why prevention cannot be reduced to a single intervention: some infections have vaccines, while others may be addressed through testing, treatment, screening or measures that reduce transmission. The relevant cancer types, health systems and available services vary substantially.
HPV provides one of the clearest examples of a cancer prevention pathway. Persistent infection with high-risk HPV types is the main cause of cervical cancer, and IARC says vaccination and cervical screening programs are available. But the existence of effective tools does not guarantee their delivery or uptake, especially where immunization, screening and follow-up care are limited.
Prevention potential, with important limits
The findings reinforce a public-health opportunity rather than offering individual medical guidance. Vaccination against HPV and hepatitis B can prevent infections that cause some cancers. For other infections, appropriate testing and treatment can be important parts of prevention and care, but the right approach depends on a person’s circumstances and local medical guidance. People considering testing for an infection such as H. pylori should discuss whether it is appropriate with a clinician or local health service.
Gary Clifford, the study’s senior author, described infection-associated cancers as unusually actionable in Scientific American’s coverage, because the underlying infections can in different settings be prevented, detected or treated. That does not mean every infection-associated cancer is immediately avoidable: vaccines do not cover every cancer-causing infection, and screening programs require repeated access.
The analysis also cannot establish how much cancer would be prevented by expanding a particular program, because it was not a clinical trial or a study following a newly enrolled group of patients. It instead quantifies the scale of cancers attributable to infections already recognized as carcinogenic. For health agencies, the 12% estimate offers a measure of what could be addressed through sustained infection control alongside broader cancer prevention, diagnosis and treatment efforts.
